Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.
2.

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME.

BMC Cancer. 2019 Mar 7;19(1):205. doi: 10.1186/s12885-019-5401-2.

3.

Breast cancer stem cells and the challenges of eradication: a review of novel therapies.

Saeg F, Anbalagan M.

Stem Cell Investig. 2018 Oct 31;5:39. doi: 10.21037/sci.2018.10.05. eCollection 2018. Review.

4.

Identification of novel heterozygous Apex 1 gene variant (Glu87Gln) in patients with head and neck cancer of Indian origin.

Abarna R, Dutta D, Sneha P, George Priya Doss C, Anbalagan M.

J Cell Biochem. 2018 Nov;119(11):8851-8861. doi: 10.1002/jcb.27138. Epub 2018 Aug 4.

PMID:
30076617
5.

Inhibition of breast tumor growth in mice after treatment with ceramide analog 315.

Ponnapakkam T, Saulsberry T, Hill T, Hill-Odom M, Goyal N, Anbalagan M, Liu J, Foroozesh M.

Anticancer Drugs. 2018 Oct;29(9):898-903. doi: 10.1097/CAD.0000000000000675.

PMID:
30044300
6.

Effect of Daytime Blue-enriched LED Light on the Nighttime Circadian Melatonin Inhibition of Hepatoma 7288CTC Warburg Effect and Progression.

Dauchy RT, Wren-Dail MA, Dupepe LM, Hill SM, Xiang S, Anbalagan M, Belancio VP, Dauchy EM, Blask DE.

Comp Med. 2018 Aug 1;68(4):269-279. doi: 10.30802/AALAS-CM-17-000107. Epub 2018 Jun 6.

7.

Photocatalytic degradation of synthetic food dye, sunset yellow FCF (FD&C yellow no. 6) by Ailanthus excelsa Roxb. possessing antioxidant and cytotoxic activity.

Deepika S, Harishkumar R, Dinesh M, Abarna R, Anbalagan M, Roopan SM, Selvaraj CI.

J Photochem Photobiol B. 2017 Dec;177:44-55. doi: 10.1016/j.jphotobiol.2017.10.015. Epub 2017 Oct 12.

PMID:
29049940
8.

Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.

Anbalagan M, Sheng M, Fleischer B, Zhang Y, Gao Y, Hoang V, Matossian M, Burks HE, Burow ME, Collins-Burow BM, Hangauer D, Rowan BG.

Mol Cancer Res. 2017 Nov;15(11):1491-1502. doi: 10.1158/1541-7786.MCR-16-0297-T. Epub 2017 Jul 27.

9.

IGF2BP1: a novel binding protein of p38 MAPK.

Rini J, Anbalagan M.

Mol Cell Biochem. 2017 Nov;435(1-2):133-140. doi: 10.1007/s11010-017-3062-5. Epub 2017 May 11.

PMID:
28497370
10.

Expression, purification and immobilization of tannase from Staphylococcus lugdunensis MTCC 3614.

Chaitanyakumar A, Anbalagan M.

AMB Express. 2016 Dec;6(1):89. doi: 10.1186/s13568-016-0261-5. Epub 2016 Oct 4.

11.

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.

Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME.

Noncoding RNA. 2016 Sep 21;2(3). pii: E8. doi: 10.3390/ncrna2030008.

12.

Human Adipose Tissue-Derived Stromal/Stem Cells Promote Migration and Early Metastasis of Head and Neck Cancer Xenografts.

Rowan BG, Lacayo EA, Sheng M, Anbalagan M, Gimble JM, Jones RK, Joseph WJ, Friedlander PL, Chiu ES.

Aesthet Surg J. 2016 Jan;36(1):93-104. doi: 10.1093/asj/sjv090. Epub 2015 Jun 10.

PMID:
26063833
13.

Somatic Mutations in Catalytic Core of POLK Reported in Prostate Cancer Alter Translesion DNA Synthesis.

Yadav S, Mukhopadhyay S, Anbalagan M, Makridakis N.

Hum Mutat. 2015 Sep;36(9):873-80. doi: 10.1002/humu.22820. Epub 2015 Jun 25.

14.

Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.

Anbalagan M, Rowan BG.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:264-72. doi: 10.1016/j.mce.2015.01.016. Epub 2015 Jan 15. Review.

PMID:
25597633
15.

Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.

Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG, Blask DE, Hill SM.

Cancer Res. 2014 Aug 1;74(15):4099-110. doi: 10.1158/0008-5472.CAN-13-3156.

16.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9.

17.

Human adipose tissue-derived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts.

Rowan BG, Gimble JM, Sheng M, Anbalagan M, Jones RK, Frazier TP, Asher M, Lacayo EA, Friedlander PL, Kutner R, Chiu ES.

PLoS One. 2014 Feb 28;9(2):e89595. doi: 10.1371/journal.pone.0089595. eCollection 2014.

18.

Arsenic inhibits the adipogenic differentiation of mesenchymal stem cells by down-regulating peroxisome proliferator-activated receptor gamma and CCAAT enhancer-binding proteins.

Yadav S, Anbalagan M, Shi Y, Wang F, Wang H.

Toxicol In Vitro. 2013 Feb;27(1):211-9. doi: 10.1016/j.tiv.2012.10.012. Epub 2012 Oct 26.

PMID:
23108036
19.

Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.

Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG.

Mol Cancer Ther. 2012 Sep;11(9):1936-47. doi: 10.1158/1535-7163.MCT-12-0146. Epub 2012 Jul 10.

20.

Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.

Anbalagan M, Moroz K, Ali A, Carrier L, Glodowski S, Rowan BG.

PLoS One. 2012;7(3):e33017. doi: 10.1371/journal.pone.0033017. Epub 2012 Mar 22.

21.

Post-translational modifications of nuclear receptors and human disease.

Anbalagan M, Huderson B, Murphy L, Rowan BG.

Nucl Recept Signal. 2012;10:e001. doi: 10.1621/nrs.10001. Epub 2012 Feb 27. Review.

22.

JNK1 and JNK2 play redundant functions in Myc-induced B cell lymphoma formation.

Anbalagan M, Sabapathy K.

Int J Cancer. 2012 Apr 15;130(8):1967-9. doi: 10.1002/ijc.26207. Epub 2011 Aug 16. No abstract available.

23.

KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.

Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG.

Breast Cancer Res Treat. 2012 Apr;132(2):391-409. doi: 10.1007/s10549-011-1513-3. Epub 2011 Apr 21.

PMID:
21509526
24.

Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor.

Thomas S, Chigurupati S, Anbalagan M, Shah G.

Mol Endocrinol. 2006 Aug;20(8):1894-911. Epub 2006 Mar 30.

PMID:
16574742
25.

Role of estrogen in regulation of cellular differentiation: a study using human placental and rat Leydig cells.

Yashwanth R, Rama S, Anbalagan M, Rao AJ.

Mol Cell Endocrinol. 2006 Feb 26;246(1-2):114-20. Epub 2006 Jan 18. Review.

PMID:
16413111
26.
27.

Comparison of target concentration intervention strategy with conventional dosing of digoxin.

Rajendran SD, Rao YM, Thanikachalam S, Muralidharan TR, Anbalagan M.

Indian Heart J. 2005 May-Jun;57(3):265-7.

PMID:
16196188
28.

Collagen IV-mediated signalling is involved in progenitor Leydig cell proliferation.

Anbalagan M, Rao AJ.

Reprod Biomed Online. 2004 Oct;9(4):391-403.

PMID:
15511338
29.

DD-RT-PCR identifies 7-dehydrocholesterol reductase as a key marker of early Leydig cell steroidogenesis.

Anbalagan M, Yashwanth R, Jagannadha Rao A.

Mol Cell Endocrinol. 2004 Apr 30;219(1-2):37-45.

PMID:
15149725
30.

LCN6, a novel human epididymal lipocalin.

Hamil KG, Liu Q, Sivashanmugam P, Anbalagan M, Yenugu S, Soundararajan R, Grossman G, Rao AJ, Birse CE, Ruben SM, Richardson RT, Zhang YL, O'Rand MG, Petrusz P, French FS, Hall SH.

Reprod Biol Endocrinol. 2003 Nov 14;1:112.

32.

Community leaders involvement in leprosy health education.

Kumar A, Thangavel N, Durgambal K, Anbalagan M.

Indian J Lepr. 1984 Oct-Dec;56(4):901-11.

PMID:
6549462
33.

Community awareness about leprosy and participation in National Leprosy Control Programme.

Kumar A, Prasad NS, Sirumban P, Anbalagan M, Durgambal K.

Lepr India. 1983 Oct;55(4):701-11.

PMID:
6668929
34.

Utilization of medical agencies and treatment compliance by urban (Madras) leprosy patients.

Kumar A, Sivaprasad N, Anbalagan M, Thangavel N, Durgambal K.

Lepr India. 1983 Apr;55(2):322-32.

PMID:
6632787
35.

Socio-economic experiences of leprosy patients.

Kumar A, Anbalagan M.

Lepr India. 1983 Apr;55(2):314-21.

PMID:
6632786
36.

Illness and service utilization behaviours of leprosy patients.

Kumar A, Anbalagan M.

Lepr India. 1982 Apr;54(2):338-47.

PMID:
6982374

Supplemental Content

Loading ...
Support Center